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BACKGROUND AND PURPOSE
Leukotrienes (LTs) are inflammatory mediators produced via the 5-lipoxygenase (5-LOX) pathway and are linked to diverse
disorders, including asthma, allergic rhinitis and cardiovascular diseases. We recently identified the benzimidazole derivative
BRP-7 as chemotype for anti-LT agents by virtual screening targeting 5-LOX-activating protein (FLAP). Here, we aimed to
reveal the in vitro and in vivo pharmacology of BRP-7 as an inhibitor of LT biosynthesis.
EXPERIMENTAL APPROACH
We analysed LT formation and performed mechanistic studies in human neutrophils and monocytes, in human whole blood
(HWB) and in cell-free assays. The effectiveness of BRP-7 in vivo was evaluated in rat carrageenan-induced pleurisy and mouse
zymosan-induced peritonitis.
KEY RESULTS
BRP-7 potently suppressed LT formation in neutrophils and monocytes and this was accompanied by impaired 5-LOX
co-localization with FLAP. Neither the cellular viability nor the activity of 5-LOX in cell-free assays was affected by BRP-7,
indicating that a functional FLAP is needed for BRP-7 to inhibit LTs, and FLAP bound to BRP-7 linked to a solid matrix.
Compared with the FLAP inhibitor MK-886, BRP-7 did not significantly inhibit COX-1 or microsomal prostaglandin E2
synthase-1, implying the selectivity of BRP-7 for FLAP. Finally, BRP-7 was effective in HWB and impaired inflammation in vivo,
in rat pleurisy and mouse peritonitis, along with reducing LT levels.
CONCLUSIONS AND IMPLICATIONS
BRP-7 potently suppresses LT biosynthesis by interacting with FLAP and exhibits anti-inflammatory effectiveness in vivo, with
promising potential for further development.
Abbreviations
12-HHT, 12-hydroxy-5,8,10-heptadecatrienoic acid; 5-HPETE, 5-hydroperoxyeicosatetraenoic acid; 5-LOX,
5-lipoxygenase; AA, arachidonic acid; cPLA2, cytosolic PLA2; cysLTs, cysteinyl LTs; DPPH, 1,1-diphenyl-2-picrylhydrazyl;
FLAP, 5-lipoxygenase-activating protein; fMLP, N-formyl-methionyl-leucyl-phenylalanine; hERG, human ether-a-go-go
gene; HWB, human whole blood; IFM, immunofluorescence microscopy; mPGES-1, microsomal PGE2 synthase-1; MTT,
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; PGC buffer, PBS pH 7.4 containing 1 mg·mL−1
glucose and 1 mM CaCl2; SDS-b, SDS-PAGE sample loading buffer; STI, soybean trypsin inhibitor
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Introduction
The leukotrienes (LTs) comprise two different classes of pro-
inflammatory lipid mediators derived from arachidonic acid
(AA) with distinct biological activities. Whereas LTB4 acts as a
chemoattractant for leukocytes and promotes immunological
responses, the cysteinyl-containing LTS (cysLTs) C4, D4 and E4
induce bronchoconstriction and mucus secretion, cause
plasma extravasation and stimulate fibrocyte proliferation
(Peters-Golden and Henderson, 2007). Consequently, inter-
vention with LTs represents a pertinent pharmacological
approach against inflammatory diseases, and anti-LT therapy
has been validated in clinical trials of asthma and allergic
rhinitis, with potential in other respiratory and allergic dis-
orders (Peters-Golden and Henderson, 2007), as well as in
cardiovascular diseases such as atherosclerosis, myocardial
infarction, stroke and abdominal aortic aneurysm (Riccioni
and Back, 2012).
The biosynthesis of LTs requires first the liberation of AA
from membrane phospholipids that is conferred by the cyto-
solic PLA2 (cPLA2) (Uozumi et al., 1997). Then, 5-lipoxygenase
(5-LOX) catalyses the incorporation of molecular oxygen
into AA to generate 5-hydroperoxyeicosatetraenoic acid
(5-HPETE) that is dehydrated by 5-LOX into LTA4 (for nomen-
clature see Alexander et al., 2013). This unstable epoxide
intermediate is further metabolized to bioactive LTs by LTA4
hydrolase (yielding LTB4) or LTC4 synthase (yielding LTC4)
(Radmark et al., 2007). Substantial experimental evidence
indicates that the cellular production of LTs from endogenous
AA requires the so-called 5-LOX-activating protein (FLAP),
which may play an essential role in AA transfer to 5-LOX
(Abramovitz et al., 1993; Ferguson et al., 2007). FLAP is a
trimeric 18 kD protein localized at the nuclear membrane and
belongs to the superfamily of membrane-associated proteins
in eicosanoid and glutathione metabolism (MAPEG). How-
ever, neither an enzymatic function nor modulation by GSH
has been revealed for FLAP thus far (Evans et al., 2008;
Ferguson, 2012). Apparently, FLAP acts as a scaffold for 5-LOX
at the nuclear envelope (Bair et al., 2012), where it facilitates
access of AA to 5-LOX (Ferguson et al., 2007). Importantly,
genetic ablation or pharmacological interference of FLAP
fully abolishes the generation of 5-LOX-derived products
(Byrum et al., 1997; Evans et al., 2008), implying its crucial
role in LT biosynthesis.
In the past, two chemotypes of FLAP inhibitors, namely
the indole series (e.g. MK886) and quinoline-based com-
pounds (e.g. BAY X-1005/DG-031) or hybrids thereof
(MK591), have been developed and evaluated in clinical
trials, but these compounds were not further explored (Evans
et al., 2008; Sampson, 2009; Ferguson, 2012). Recent
re-assessment of FLAP inhibitors of the indole series provided
GSK2190915 as a promising candidate that is currently
undergoing phase II trials in patients with asthma (Stock
et al., 2011; Bain et al., 2013; Follows et al., 2013; Kent et al.,
2013; Snowise et al., 2013). Also, the anti-inflammatory com-
pound licofelone, which was originally developed as a dual
inhibitor of the COX and 5-LOX pathways (Laufer et al.,
1994a,b), targets FLAP (Fischer et al., 2007) and has reached
clinical phase III for osteoarthritis (Raynauld et al., 2009).
Inspired by the therapeutic potential of FLAP inhi-
bitors, we attempted to discover novel chemotypes using a
virtual screening approach targeting FLAP. By means of
a combined ligand- and structure-based pharmacophore
model, we recently identified BRP-7 [1-(2-chlorobenzyl)-2-(1-
(4-isobutylphenyl)ethyl)-1H-benzimidazole] (Figure 1A) as a
LT synthesis inhibitor in intact neutrophils, without direct
effects on 5-LOX (Banoglu et al., 2012). Here, we show that (i)
BRP-7 inhibits 5-LOX product synthesis with typical features
of well-recognized FLAP inhibitors; (ii) is effective in human
whole blood (HWB); and (iii) has anti-inflammatory effects in
two LT-related functional in vivo models, suggesting promis-
ing potential for further development.
Methods
Materials
BRP-7 was synthesized and characterized as reported
previously (Banoglu et al., 2012). RSC-3388 (N-{(2S,4R)-4-
(biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-(2,4-difluoroben-
zoyl)-benzoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazo-
lidin-5-ylidenemethyl)-phenyl]acrylamide) was purchased
from Calbiochem (Bad Soden, Germany), zileuton from
Sequoia Research Products (Oxford, UK), MK886 from
Cayman Chemical (Ann Arbor, MI, USA), and zymosan and
λ-carrageenan type IV isolated from Gigartina aciculairis and
Gigartina pistillata from Sigma (Milan, Italy). HPLC solvents
were from VWR International GmbH (Darmstadt, Germany).
AA, Ca2+ ionophore A23187, celecoxib, LPS, N-formyl-
methionyl-leucyl-phenylalanine (fMLP), indomethacin and
all other fine chemicals were from Sigma (Taufkirchen,
Germany), unless stated otherwise. BRP-7 probes for fishing
approach were synthesized as indicated in the Supporting
Information Appendix S1.
Cells
Neutrophils and monocytes were isolated from buffy coats
from adult healthy volunteers obtained at the Institute of
Transfusion Medicine, University Hospital Jena. Neutrophils
were immediately isolated by dextran sedimentation and
centrifugation on Nycoprep cushions (PAA Laboratories,
Linz, Austria) and hypotonic lysis of erythrocytes as described
previously (Pergola et al., 2008). Monocytes were separated
from peripheral blood mononuclear cells by adherence to
culture flasks as described previously (Pergola et al., 2011). To
exclude any cytotox effects of the test compounds, cell viabil-
ity was analysed by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assay as described
previously (Tretiakova et al., 2008).
Determination of 5-LOX product formation
For assays in intact cells, neutrophils or monocytes [5 × 106
and 2 × 106 mL−1, respectively; in PBS (pH 7.4) containing
1 mg·mL−1 glucose and 1 mM CaCl2 (PGC buffer); incubation
volume, 1 mL] were pre-incubated with the compounds or
vehicle (0.1% DMSO) for 15 min at 37°C. Then, 2.5 μM
A23187 plus AA was added. For neutrophils, 40 μM AA was
used as a standard concentration, as in previous studies (Werz
et al., 2002), whereas 10 μM AA was used for monocytes,
because of substrate inhibition at higher AA concentrations.
The reaction was stopped after 10 min with 1 mL methanol
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Figure 1
BRP-7 has features resembling other FLAP inhibitors. (A) BRP-7 structure. (B) 5-LOX product formation in human neutrophils stimulated with
A23187 (2.5 μM), without or with AA (40 μM), after pre-incubation with BRP-7 or vehicle (0.1% DMSO). (C) Effects of 10 μM BRP-7, 100 nM
MK886 or 10 μM zileuton on 5-LOX product formation in intact neutrophils and in neutrophil homogenates, and on the activity of human
recombinant 5-LOX. Intact neutrophils were stimulated with A23187 (2.5 μM). For homogenates and purified 5-LOX, test compounds were
added 5 min before the addition of 1 mM Ca2+ plus 40 μM AA. (D) Effects of BRP-7 on the activity of human recombinant 5-LOX at increasing
AA substrate concentrations. (E) Reducing conditions do not restore 5-LOX inhibition by BRP-7. GSH (5 mM) or vehicle was added to
homogenates of neutrophils, prior to BRP-7 addition. After 10 min on ice, 1 mM CaCl2 and 40 μM AA were added for 10 min at 37°C. The 100%
controls correspond to 5-LOX products in (B, C, E) intact cells, 117.5 ± 17.5 and 831.3 ± 50.9 ng·mL−1, for A23187 or A23187 + AA, respectively;
purified 5-LOX, 947.8 ± 125.2 ng·mL−1; homogenates, 484.7 ± 72 ng·mL−1 and 429.6 ± 111.8 ng·mL−1, without GSH and after addition of 5 mM
GSH, respectively; (D) 37.9 ± 6.1, 153.1 ± 4.6, 610.3 ± 37.8 and 812.3 ± 22.6 ng·mL−1, in the presence of 1, 3, 10 and 20 μM AA respectively.
(F) Cell viability of human neutrophils after 30 min of pre-incubation at 37°C with vehicle (0.1% DMSO), 10 μM BRP-7 or 1% Triton X-100. (G)
Analysis of radioactivity in supernatants of [3H]-AA-labelled neutrophils after pre-incubation with 10 μM BRP-7, 100 nM MK886, 10 μM zileuton
or 1 μM cPLA2 inhibitor (RSC-3388) and stimulation with 2.5 μM A23187 plus 50 μM thiomersal; 100% corresponds to 18 073 ± 1735 cpm. Data
are means + SEM; n = 3–9; *P < 0.05; **P < 0.01; ***P < 0.001 (B) versus inhibition by the corresponding BRP-7 concentration without the addition
of AA; (C–F) versus 100% control; ANOVA plus Bonferroni.
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and 30 μL 1 N HCl, and 200 ng PGB1 and 500 μL of PBS were
added.
For assays in cell homogenates, 1 mM EDTA was added to
cells re-suspended in PBS. Samples were cooled on ice
(5 min), sonicated (3 × 10 s) at 4°C, and 1 mM ATP and 1 mM
DTT were added, as indicated. For assays with isolated 5-LOX,
Escherichia coli BL21 was transformed with pT3-5LO plasmid,
human recombinant 5-LOX protein was expressed at 30°C as
described previously (Pergola et al., 2012), and partially puri-
fied 5-LOX was added to 1 mL of a 5-LOX reaction mix (PBS,
pH 7.4, 1 mM EDTA, 1 mM ATP). Samples (0.5–2 μg of par-
tially purified 5-LOX, resulting in about 1000 ng·mL−1 5-LOX
products in an activity test performed with 20 μM AA; or cell
homogenates, corresponding to 5 × 106 and 2 × 106 cells·mL−1
per sample, for neutrophils and monocytes, respectively)
were incubated for 10 min at 4°C with vehicle or test com-
pounds, pre-warmed for 30 s at 37°C, and 2 mM CaCl2 and
the indicated concentrations of AA were added. The reaction
was stopped as indicated for intact cells.
For assays in HWB, freshly withdrawn blood from healthy
adult donors was obtained by venipuncture and collected in
monovettes containing 16 IE heparin·mL−1. Aliquots of 2 mL
were primed with 1 μg·mL−1 LPS for 15 min at 37°C, followed
by incubation with vehicle (0.1% DMSO) or test compounds
for 15 min at 37°C, and stimulation with 1 μM fMLP for
15 min at 37°C. Samples were prepared for extraction of
metabolites and then extracted and analysed by HPLC as
described previously (Pergola et al., 2012).
5-LOX products include LTB4, its all-trans isomers and
5-HPETE. The cysteinyl leukotrienes (cysLTs) C4, D4 and E4
were not detected. For the determination of cysLTs in super-
natants of monocytes, a cysLT ELISA kit from Enzo Life Sci-
ences International Inc. (Lörrach, Germany) was used.
Determination of 3H-labelled AA release
Release of 3H-labelled AA from neutrophils and monocytes
was analysed as previously described (Fischer et al., 2005).
Briefly, freshly isolated cells were re-suspended at 1 × 107 in
1 mL of RPMI 1640 medium containing 5 nM [3H]-AA (cor-
responding to 0.5 μCi·mL−1, specific activity 200 Ci·mmol−1)
and incubated for 120 min at 37°C in 5% CO2 atmosphere.
Cells were then washed twice with PBS containing 1 mg·mL−1
glucose and 2 mg·mL−1 fatty acid-free bovine albumin to
remove unincorporated [3H]-AA. Labelled cells (2 × 107 mL−1
PMNL and 5 × 106 mL−1 monocytes) were re-suspended in
1 mL of PGC containing 2 mg·mL−1 fatty acid-free bovine
albumin and pre-incubated with 0.1% DMSO or test com-
pounds (15 min, 37°C). Neutrophils were stimulated with
2.5 μM A23187 in the presence of 50 μM thiomersal to block
the re-acylation of unconverted AA into membranes (Zarini
et al., 2006), and monocytes were stimulated with 2.5 μM
A23187. The samples were then placed on ice, centrifuged
and aliquots (300 μL) of the supernatants were assayed for
radioactivity by scintillation counting (Micro Beta Trilux;
PerkinElmer, Waltham, MA, USA).
Analysis of subcellular redistribution
of 5-LOX
For analysis of 5-LOX subcellular redistribution, neutrophils
(3 × 107 mL−1 PGC buffer) were pre-incubated with 0.1%
DMSO or BRP-7 for 15 min at 37°C and stimulated with
2.5 μM A23187. After 5 min, the reaction was stopped on ice
and samples were centrifuged (200× g for 5 min at 4°C). Sub-
cellular fractionation was performed by mild detergent (0.1%
NP40) lysis, yielding a nuclear and a non-nuclear fraction as
described previously (Werz et al., 2001). Aliquots (20 μL) of
nuclear and non-nuclear fractions were analysed by SDS-
PAGE and Western blotting as described previously (Pergola
et al., 2012). 5-LOX antiserum (1551, AK7, kindly provided by
Dr Olof Rådmark, Karolinska Institutet, Stockholm, Sweden)
was used at 1:100 dilution; alkaline phosphatase-conjugated
IgGs (Sigma-Aldrich) were used at 1:1000 dilution. Proteins
were visualized with nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolylphosphate in detection buffer [100 mM Tris/
HCl (pH 9.5), 100 mM NaCl, 5 mM MgCl2].
Analysis of 5-LOX subcellular localization by indirect
immunofluorescence microscopy (IFM) was performed as
described previously (Pergola et al., 2008; 2011). In brief, neu-
trophils or monocytes were pre-incubated with 0.1% DMSO
or test compounds (15 min at 37°C), then placed onto poly-
L-lysine (MW 150 000–300 000; Sigma-Aldrich)-coated glass
coverslips, and activated by the addition of 2.5 μM A23187 for
3 min at 37°C. Cells were fixed in methanol (−20°C, 30 min)
and permeabilized with 0.1% Tween 20 in PBS (RT, 10 min),
followed by three washing steps with PBS. Samples were
blocked with 10% non-immune goat serum (Invitrogen,
Darmstadt, Germany) for 10 min at RT, washed with PBS and
incubated with mouse anti-5-LOX (kindly provided by Dr
Dieter Steinhilber, University of Frankfurt, Germany) and
rabbit anti-FLAP (1:200; Abcam, Cambridge, UK) for 1 h at RT.
The coverslips were washed 10 times with PBS, incubated for
10 min at RT in the dark with Alexa Fluor 488 goat anti-rabbit
(1:1500) and Alexa Fluor 555 anti-mouse IgG (1:1000) (Invit-
rogen) diluted in PBS, and washed 10 times with PBS. Where
indicated, the DNA was stained with 0.1 μg·mL−1 DAPI in PBS
for 3 min at RT in the dark. The coverslips were then mounted
on glass slides with Mowiol (Calbiochem) containing 2.5%
n-propyl gallate (Sigma-Aldrich). The fluorescence was visual-
ized with a Zeiss Axio Observer.Z1 microscope (Carl Zeiss,
Jena, Germany) and a Plan-Apochromat 100×/1.40 Oil DIC
M27 objective. Images were taken with an AxioCam MR3
camera and were acquired, cut, linearly adjusted in the overall
brightness and contrast, and exported to TIF by the AxioVi-
sion 4.8 software (Carl Zeiss).
Immobilization of BRP-7 derivatives and
pull-down assays
Toyopearl AF-Amino-650 M resin (Tosoh Bioscience, Stutt-
gart, Germany) was washed five times with water and acetate
buffer (0.1 M sodium acetate, 0.5 M NaCl; pH 4) and once
with 80% MeOH (pH 5). Then, 100 μmol of 1a and 2a car-
boxylate analogues were solubilized in 10 mL of 80% MeOH
by adding 1 M NaOH until the compounds were completely
dissolved. Subsequently, pH was adjusted to 5 with 1 M
HCl. Toyopearl resin (500 μL) and 40 mg 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide were added to form
amides 1b and 2b (48 h, pH 5). Probes were washed with
acetate buffer and stored in 20% MeOH until use.
For preparation of nuclear membranes, 1.5 × 109 neutro-
phils were lysed by a mild detergent (0.1% NP40) lysis with
1.6 mL of lysis buffer [10 mM Tris–HCl (pH 7.4), 10 mM
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NaCl, 3 mM MgCl2, 1 mM EDTA, 0.1% NP-40, 1 mM PMSF,
60 μg·mL−1 soybean trypsin inhibitor (STI) and 10 μg·mL−1
leupeptin], vortexed (3 × 5 s), kept on ice for 10 min and
centrifuged (1000× g, 10 min, 4°C) (Werz et al., 2001). The
resulting pellets (nuclear fractions) were re-suspended in
500 μL of TKM buffer [50 mM Tris–HCl (pH 7.4), 25 mM KCl,
5 mM MgCl2, 250 mM sucrose, 1 mM EDTA, 1 mM PMSF,
60 μg·mL−1 STI and 10 μg·mL−1 leupeptin]. Nuclei were dis-
rupted by sonication (3 × 5 s), samples were cleared by
centrifugation (5 min, 10 000× g, 4°C) and the resulting
supernatants were centrifuged for 1 h at 100 000× g, for iso-
lation of membranes. The pellet was then re-suspended in
100 μL of membrane buffer [100 mM Tris–HCl (pH 7.4),
100 mM NaCl, 1 mM EDTA, 0.5 mM DTT, 5% glycerol,
0.05% Tween 20, 1 mM PMSF, 60 μg·mL−1 STI, 10 μg·mL−1
leupeptin], resulting in a protein concentration of about
6.5 mg·mL−1.
For pull-down assays, 50 μL of resin was added to 500 μL
of binding buffer [50 mM HEPES (pH 7.4), 200 mM NaCl,
1 mM EDTA] and 8 μL of the neutrophil nuclear membranes
(corresponding to about 50 μg of protein), incubated (2.5 h,
4°C) and washed three times with 500 μL of binding buffer.
Proteins were eluted with 50 μL of 2× SDS-b (SDS-PAGE
sample loading buffer) (5 min, 96°C). Equal amounts of
protein were loaded onto 16% acrylamide gels and analysed
for FLAP by Western blotting using rabbit anti-FLAP (Abcam),
anti-rabbit IRDye 800CW (Li-Cor Biosciences, Lincoln, NE,
USA), and detection with an Odyssey Infrared Imaging
System (Li-Cor Bioscience), and analysis by the Odyssey
application software (version 3.0.25).
Activity assays of COX-1 and -2, of
microsomal PGE2 synthase-1 (mPGES-1)
Activities of the purified ovine COX-1 (50 units) or human
recombinant COX-2 (20 units) (both from Cayman Chemi-
cal) were analysed as described previously (Koeberle et al.,
2008). Briefly, the COX enzymes were pre-incubated with the
test compound for 5 min at 4°C, samples were pre-warmed
for 60 s at 37°C, AA (5 μM for COX-1, 2 μM for COX-2)
was added, and after 5 min at 37°C, the COX product
12-hydroxy-5,8,10-heptadecatrienoic acid (12-HHT) was ana-
lysed by HPLC. Indomethacin (10 μM) was used as a reference
inhibitor.
To analyse the effect of BRP-7 on cellular COX-1 activity,
freshly isolated human platelets (108 mL−1 PGC buffer) were
pre-incubated with test compounds for 15 min at 37°C and
stimulated for 10 min at 37°C with 5 μM AA. The COX reac-
tion was stopped and 12-HHT was analysed as for the isolated
enzyme.
To analyse the effect of BRP-7 on cellular COX-2 activity,
A549 cells were stimulated with 2 ng·mL−1 IL-1β for 72 h
to induce COX-2 expression, washed twice with PBS,
re-suspended in PGC buffer (2 × 106 cells·mL−1) and pre-
incubated with the indicated compounds for 15 min at 37°C.
After stimulation for 15 min at 37°C with 3 μM AA, the reac-
tion was stopped on ice, the supernatants were recovered
after centrifugation at 60× g for 10 min at 4°C, and 6-keto
PGF1α formation was measured by ELISA (6-keto PGF1α from
Sapphire Bioscience, Waterloo, Australia).
Preparation of A549 cells and determination of mPGES-1
activity was performed as described previously (Koeberle
et al., 2008). In brief, cells (2 × 106 cells in 20 mL of medium)
were plated, incubated for 16 h (37°C, 5% CO2) and then the
culture medium was replaced by fresh DMEM/high glucose
(4.5 g·L−1) medium containing 2% (v v−1) FCS. mPGES-1
expression was induced by 2 ng·mL−1 IL-1β for 72 h. Cells
were sonicated and the microsomal fraction was prepared by
differential centrifugation at 10 000× g for 10 min and at
174 000× g for 1 h. The pellet was re-suspended in 1 mL of
homogenization buffer [0.1 M potassium phosphate buffer
(pH 7.4), 1 mM PMSF, 60 μg·mL−1 STI, 1 μg·mL−1 leupeptin,
2.5 mM glutathione and 250 mM sucrose] and then serially
diluted in 0.1 M potassium phosphate buffer (pH 7.4) con-
taining 2.5 mM glutathione for activity test. A dilution
leading to about 10 μM PGE2 (using 20 μM PGH2 as substrate;
incubation volume, 100 μL) was finally used for the experi-
ments. The microsomal membranes (total volume, 100 μL)
were pre-incubated with the test compounds or 0.1% DMSO.
After 15 min, PGE2 formation was initiated by the addition of
PGH2 (20 μM). After 1 min at 4°C, the reaction was termi-
nated with 100 μL of stop solution (40 mM FeCl2, 80 mM
citric acid and 10 μM of 11β-PGE2 as internal standard), and
PGE2 was separated by solid-phase extraction (RP-18 material)
and analysed by HPLC.
Evaluation of human ether-a-go-go gene
(hERG) and CYP3A4 inhibition
The experiments for evaluation of hERG and cytochrome
P450 (CYP3A4) inhibition were performed by Cyprotex Dis-
covery Ltd (Macclesfield, UK), as indicated in the Supporting
Information Appendix S1. Briefly, the hERG assay was per-
formed with CHO cells stably transfected with hERG and
electrophysiology measurements by an IonWorksTM HT
instrument (Molecular Devices Corporation, Sunnyvale, CA,
USA) and specialized multi-well plate (PatchPlateTM). For
CYP3A4 assay, the test compound was incubated with human
liver microsomes and NADPH in the presence of the specific
CYP3A4 substrate, midazolam. 1-Hydroxymidazolam was
monitored by LC-MS/MS.
Animal studies
The animal studies are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). Male
Wistar Han rats (200–230 g; Harlan, San Pietro al Natisone,
Italy, and Charles River, Calco, Italy) and male CD-1 mice
(35–40 g; Charles River) (30 rats, 50 mice) were housed at the
Department of Pharmacy (Naples, Italy) in a controlled envi-
ronment (21 ± 2°C) and provided with standard rodent chow
and water. Animals were allowed to acclimatize for 4 days
before the experiments and were subjected to a 12 h light–
12 h dark schedule. Experiments were conducted during the
light phase. Animal care was in compliance with Italian regu-
lations on protection of animals used for experimental and
other scientific purpose (Ministerial Decree 116/92) as well as
with the European Economic Community regulations (Offi-
cial Journal of the European Community L 358/1 12/18/
1986). The animal studies were approved by the local ethical
committee of the University of Naples Federico II on 10
February 2011 (approval number 2011/0017635) and on 28
June 2011 (approval number 2011/0075376).
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The carrageenan-induced pleurisy in rats was performed
as described previously (Pergola et al., 2012). Thus, BRP-7 or
MK886 at the indicated dose or vehicle (1.5 mL of 0.9% saline
solution containing 4% DMSO) was given i.p. 30 min before
λ-carrageenan type IV 1% (w v−1; 0.2 mL), which was injected
into the pleural cavity. The animals were killed by inhalation
of CO2 at 4 h, the pleural exudates were collected, the cells in
the exudates were counted and the amounts of LTB4 were
assayed by EIA kit (Cayman Chemical), according to manu-
facturer’s instructions.
For zymosan-induced peritonitis in mice, BRP-7 or
MK-886 at the indicated dose or vehicle (0.5 mL of 0.9%
saline solution containing 2% DMSO) was given i.p. 30 min
before zymosan i.p. injection (0.5 mL of suspension of
2 mg mL−1 in 0.9% w/v saline). Mice were killed by inhalation
of CO2 at the indicated time, followed by a peritoneal lavage
with 3 mL of cold PBS. Exudates were collected, the cells in
the exudates were counted and LTC4 was measured by EIA
(Cayman Chemical). Vascular permeability was assessed by
the Evans blue method according to Kolaczkowska et al.
(2002).
Statistics
Results are expressed as mean + SEM of n observations, where
n represents the number of experiments performed on differ-
ent days in duplicates or the number of animals, as indicated.
The IC50 values were determined by interpolation on semi-
logarithmic graphs and validated with GraphPad Prism soft-
ware (GraphPad, San Diego, CA, ISA). Statistical evaluation of
the data was performed by one-way ANOVA) for independent
or correlated samples, followed by Tukey’s HSD (honestly
significant difference) post hoc tests. Where appropriate, Stu-
dent’s t-test was applied. A P-value < 0.05 (*) was considered
significant.
Results
Differential inhibition of 5-LOX product
synthesis by BRP-7 in cell-based and
cell-free assays
Firstly, we studied the ability of BRP-7 to interfere with 5-LOX
product synthesis and we addressed whether BRP-7 shares
typical mechanistic properties with FLAP inhibitors. As
we observed no significant differences in the inhibitory
potency between the individual enantiomers (Sardella et al.,
2013), racemic BRP-7 was used. In agreement with our previ-
ous results (Banoglu et al., 2012), BRP-7 concentration-
dependently inhibited the formation of 5-LOX-derived
products (i.e. LTB4 and its trans isomers and 5-HPETE) in
A23187-stimulated human neutrophils (IC50 = 0.15 ±
0.08 μM; Figure 1B). However, BRP-7 did not inhibit 5-LOX
product formation in cell-free assays (i.e. human recombi-
nant 5-LOX or neutrophil homogenates), which was similar
to the FLAP inhibitor MK886, whereas the direct 5-LOX
inhibitor zileuton was active in this respect (Figure 1C).
Failure to inhibit 5-LOX in such cell-free assays was inde-
pendent of the substrate concentration (Figure 1D), exclud-
ing a competitive mode of action, and may indicate the lack
of a direct effect on 5-LOX, but it may also be related to a lack
of effect under non-reducing conditions, as reported for non-
redox-type 5-LOX inhibitors (Werz et al., 1998). In contrast to
this class of compounds, however, inclusion of GSH in
homogenates did not restore the inhibitory effect of BRP-7 on
5-LOX (Figure 1E). Also, BRP-7 was ineffective as a radical
scavenger in a DPPH (1,1-diphenyl-2-picrylhydrazyl) assay
(not shown), excluding interference by redox-related mecha-
nisms. Together, direct interference of BRP-7 with 5-LOX can
be excluded. Moreover, non-specific effects of BRP-7 in intact
cells due to cell toxicity are unlikely because BRP-7 had no
significant effects on cell viability (Figure 1F). Of interest, as
described for MK886 (Fischer et al., 2007), the efficiency of
BRP-7 in A23187-stimulated neutrophils was significantly
reduced when excess (40 μM) exogenous AA was included
(Figure 1A), despite it not inducing a significant inhibition of
AA release from [3H]-AA-labelled neutrophils (Figure 1G).
BRP-7 blocks 5-LOX co-localization with
FLAP at the nuclear envelope in neutrophils
FLAP inhibitors were shown to block 5-LOX translocation to
the nucleus seemingly by preventing the association between
5-LOX/FLAP (Evans et al., 2008). As shown in Figure 2A, upon
stimulation of neutrophils with A23187, cytosolic 5-LOX is
translocated to the nucleus, and this was concentration-
dependently inhibited by BRP-7, starting at 1 μM, although
complete inhibition was not observed even at 10 μM. IFM
allowed more detailed analysis of 5-LOX subcellular localiza-
tion and also of FLAP (Figure 2B). In unstimulated cells, FLAP
was localized to the nuclear envelope, whereas 5-LOX was
distributed within the cytosol, and co-localization of 5-LOX
and FLAP was not evident. Upon A23187 stimulation, 5-LOX
clearly co-localized with FLAP at the nuclear envelope. Pre-
incubation of neutrophils with BRP-7 or MK886 (10 μM and
100 nM, concentrations that completely inhibited 5-LOX
product formation) prevented the 5-LOX association with
FLAP, although only to a partial extent, indicating that inhi-
bition of 5-LOX translocation by FLAP inhibitors is not
directly related to LT suppression.
To analyse the interaction of BRP-7 with FLAP, we used an
affinity chromatography method using an insoluble BRP-7
matrix and solubilized FLAP (from neutrophil membranes) as
the protein source. Thus, the 2′-chlorine in BRP-7 was
replaced by a methylene ether linked either via an amide
function to a sepharose matrix (yielding matrix 1b) or to
ethyl carboxylate (yielding 1a) (Figure 3A). Compound 1a
inhibited 5-LOX product synthesis, although with a lower
potency as compared to BRP-7 (IC50 for 1a = 2.6 ± 1.1 μM).
The truncated analogues thereof, that is, matrix 2b and com-
pound 2a, were used as negative, inactive controls (Figure 3A;
IC50 for 2a was >10 μM). Interestingly, FLAP was enriched in
pull-downs using matrix 1b that carries the bioactive probe,
as compared to matrix 2b (Figure 3B). Excess BRP-7 (100 μM)
prevented the FLAP enrichment in pull-downs with matrix
1b (Figure 3B), as expected. 5-LOX protein was not detected
in the pull-downs (not shown), excluding possible indirect
effects on FLAP.
Cellular pharmacology of BRP-7 in monocytes
Besides neutrophils, monocytes are a major source of LTs
(Surette et al., 1993; Pergola et al., 2011). We thus determined
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the effects of BRP-7 on 5-LOX product formation in human
monocytes stimulated with A23187 in the presence or
absence of exogenous AA (10 μM). BRP-7 potently inhibited
the formation of 5-LOX products (LTB4 and its trans isomers
and 5-HPETE) in the absence of AA with an IC50 = 0.04 ±
0.01 μM (Figure 4A). In the presence of 10 μM AA, BRP-7 still
inhibited 5-LOX activity, but, similar to that observed for
neutrophils, with lower potency (IC50 = 0.25 ± 0.1 μM). In
contrast to neutrophils, monocytes may convert LTA4 by LTC4
synthase to LTC4, and BRP-7 efficiently also suppressed the
synthesis of cysLTs (IC50 = 0.03 ± 0.01 μM; Figure 4B). In
monocyte homogenates, BRP-7 up to 0.3 μM failed to signifi-
cantly inhibit 5-LOX activity and this was also found for
MK886 but not for zileuton, as expected (Figure 4A). Analysis
of cell viability revealed no compromising effect of BRP-7
(10 μM) as compared to staurosporine (1 μM), used as control
Figure 2
BRP-7 reduces the nuclear translocation of 5-LOX in human neutrophils. Analysis of 5-LOX localization by (A) subcellular fractionation and (B) IFM.
(A) Neutrophils were pre-incubated for 15 min at 37°C with vehicle (0.1% DMSO) or BRP-7 and then stimulated with 2.5 μM A23187 for 5 min
at 37°C and lysed by mild detergent (0.1% NP-40). Non-nuclear (non-nucl) and nuclear (nucl) fractions were analysed by Western blot and
densitometric analysis was performed. Data are given as means + SEM; n = 3. (B) Neutrophils were pre-incubated with vehicle (0.1% DMSO),
BRP-7 (10 μM), MK-886 (100 nM) and stimulated by A23187 (2.5 μM; 3 min). Cells were fixed, permeabilized and incubated with mouse
anti-5-LOX and rabbit anti-FLAP, followed by Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-mouse IgG. Red: 5-LOX; green:
FLAP. Scale bar: 10 μm. The pictures shown are representative of three similar samples.
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(Figure 4C). In addition to 5-LOX products, monocytes also
generate other related eicosanoids from AA including 12- and
15-HPETE, as well as the COX product 12-HHT (Pergola et al.,
2011). However, neither the formation of 12- and 15-HPETE,
nor 12-HHT, nor the amount of radioactivity in the superna-
tant (from [3H]-AA) after A23187 stimulation was affected by
10 μM BRP-7 (Figure 4D,E), implying it has a selective effect
on 5-LOX product synthesis.
As observed previously (Pergola et al., 2011), the bulk of
the 5-LOX protein in resting monocytes was localized inside
the nucleus, whereas FLAP was found at the nuclear mem-
brane (Figure 4F). A23187 stimulation redistributed 5-LOX to
the nuclear membrane, where it co-localized with FLAP.
BRP-7 and MK886 efficiently prevented the co-localization of
5-LOX and FLAP, even though the compounds failed to
restore the pattern to that of resting cells with clear intranu-
clear 5-LOX. These data indicate that FLAP inhibitors prevent
the association of 5-LOX with FLAP in stimulated monocytes
but do not generally interfere with the redistribution of
5-LOX in these stimulated cells.
Effects of BRP-7 on COX-1 and -2, mPGES-1,
CYP3A4 and hERG
FLAP inhibitors such as MK886 tend also to inhibit other
enzymes involved in the AA cascade, including COX-1 and
mPGES-1 (Claveau et al., 2003; Koeberle et al., 2009), which
let us to evaluate their selectivity. BRP-7 (at 10 μM) did not
inhibit COX-1 or COX-2 in both cell-free (Figure 5A,B) and
cellular (Figure 5C,D) assays, and also failed to significantly
block mPGES-1 activity in a cell-free assay (Figure 5E). Ref-
erence compounds for COX enzymes (indomethacin) and
for mPGES-1 (MK886) confirmed the functionality of the
assays respectively. Finally, we tested the ability of BRP-7 to
inhibit CYP3A4, the most common CYP-isoforms in drug
metabolism for prediction of probable drug interactions.
BRP-7 did not significantly inhibit CYP3A4 activity up to
25 μM as compared to the reference drug ketoconazole
(which showed an IC50 of 0.04 μM; n = 7). In addition,
BRP-7 as a lipophilic benzimidazole derivative could bind to
the human ether-a-go-go gene (hERG) voltage-gated potas-
sium channel thereby prolonging the drug-induced QT
interval (Yao et al., 2008). However, there was no appreci-
able hERG inhibition up to 10 μM (0.97% inhibition;
n = 19).
Efficiency of BRP-7 in HWB and efficacy
in vivo
Given the favourable efficiency and selectivity of BRP-7, we
next aimed to estimate its effectiveness and pharmacological
relevance under more complex systems and in vivo. Thus, we
analysed 5-LOX product synthesis in HWB stimulated with
the pathophysiological relevant stimuli LPS and fMLP, which
includes important variables such as plasma protein binding,
presence of co-factors and cell–cell interactions. BRP-7 signifi-
cantly inhibited 5-LOX product synthesis in blood with an
IC50 of 4.8 ± 1 μM (Figure 6A), which is slightly higher, in the
single-digit micromolar range, than that for MK886 (IC50 of
1.1 ± 0.4 μM; not shown).
We next studied the effects of BRP-7 in vivo using the
carrageenan-induced pleurisy in rats, an animal model of
acute inflammation involving 5-LOX. The i.p. pretreatment
(30 min before carrageenan administration) of rats with 10,
20 or 30 mg·kg−1 of BRP-7 significantly reduced the inflam-
matory reaction, measured as exudate volume, inflammatory
cell numbers and LTB4 levels in the pleural exudates (Table 1,
Figure 6B), with an ID50 value for LTB4 inhibition of about
20 mg·kg−1. For comparison, the reference FLAP inhibitor
MK886 (at the maximally effective dose of 1 mg·kg−1, i.p.) also
significantly reduced exudate volume, infiltrated cells and
LTB4 (Table 1, Figure 6B). In zymosan-induced peritonitis in
mice, another well-recognized model of acute inflammation,
BRP-7 significantly impaired levels of LTC4 with an ID50 of
about 20 mg·kg−1 (Figure 6C). At this dose, BRP-7 reduced
vascular permeability by 38% and inhibited neutrophil infil-
tration by 30% (Table 2), compared to reductions of 76 and
37% by MK886 (1 mg·kg−1), respectively, implying that BRP-
7-induced inhibition of LT biosynthesis in vivo is associated
with its anti-inflammatory efficacy.
Figure 3
FLAP binds to an immobilized BRP-7 derivative. (A) Structures of BRP-7 derivatives used for the evaluation of IC50 values for 5-LOX products in
A23187-stimulated human neutrophils (compounds 1a and 2a), and for protein fishing experiments after coupling on amino-activated Toyopearl
AF-Amino-650 (compounds 1b and 2b). Compounds 2a and 2b were used as inactive controls. In (B), nuclear membrane proteins of human
neutrophils were incubated with 1b or 2b functionalized beads. For 1b functionalized beads, competition was performed with 100 μM BRP-7,
as indicated. Precipitated proteins were analysed by Western blot for FLAP or by Coomassie staining followed by densitometry. Similar results were
obtained in two additional experiments.
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Figure 4
Cellular pharmacology of BRP-7 in humanmonocytes. (A, B) Effect of BRP-7, 100 nMMK886 or 10 μMzileuton on (A) LTB4 + 5-H(P)ETE and (B) cysLT
formation in intact human monocytes stimulated with A23187 (2.5 μM) in the presence or absence of exogenous AA (10 μM) or in monocyte
homogenates treated with 1 mM Ca2+ plus 10 μMAA. Pre-incubation with compounds or vehicle (0.1% DMSO) was performed for 15 min at 37°C
for intact cells or 5 min at 4°C for homogenates. The 100%controls correspond to (A) A23187, 42.0 ± 4.1 ng·mL−1; A23187 +AA, 29.2 ± 1.3 ng·mL−1;
homogenates, 49.7 ± 13.2 ng·mL−1; (B) 583 ± 85 pg·mL−1. (C) Cell viability of humanmonocytes after a 30 min pre-incubation at 37°C with vehicle
(0.1% DMSO), 10 μM BRP-7 or 1 μM staurosporine (stsp). (D) Effect of 10 μM BRP-7 on the formation of 12-HETE, 15-HETE and 12-HHT in
monocytes stimulated for 10 min at 37°C with A23187 (2.5 μM). The 100% controls correspond to 12-HETE, 127.5 ± 27.2 ng·mL−1; 15-HETE, 3.9
± 1.2 ng·mL−1; 12-HHT, 19.4 ± 2.6 ng·mL−1. (E) Analysis of radioactivity in supernatants of [3H]-AA-labelled monocytes after pre-incubation with
10 μM BRP-7 or 1 μM cPLA2 inhibitor (RSC-3388) and stimulation with 2.5 μM A23187;100% corresponds to 25 437 ± 4226 cpm. (F) Analysis of
5-LOX localization by indirect IFM after pre-incubation of adherent monocytes for 15 min at 37°C with vehicle (0.1% DMSO), BRP-7 (10 μM) or
MK-886 (100 nM) and stimulation with A23187 (2.5 μM, 3 min). Cells were fixed, permeabilized and incubated with mouse anti-5-LOX and rabbit
anti-FLAP, followed by Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 555 goat anti-mouse IgG and DAPI. Red, 5-LOX; green, FLAP; blue, DNA.
Scale bar: 10 μm. Sections were generated with the AxioVision 4.8 software from 0.2 μm step Z stacks of adherent monocytes (adhesion substrate
on the right side of the view). The cutting plane is indicated in the overlays by white triangles. In (A)–(C), data are expressed as percentage of vehicle
control (100%) and are means + SEM; n = 3; *P < 0.05; **P < 0.01; ***P < 0.001 (A) versus 100% control; ANOVA plus Bonferroni.
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Discussion and conclusions
There is currently a strong interest in the development of
FLAP inhibitors because of their promising potential as thera-
peutics against inflammatory and allergic disorders as well as
against cardiovascular disease (Evans et al., 2008; Back, 2009;
Sampson, 2009; Ferguson, 2012; Bain et al., 2013; Kent et al.,
2013). However, recent development of drug candidates tar-
geting FLAP (e.g. GSK2190915) concentrates on the classical
FLAP inhibitor structure of MK886 and novel chemotypes are
rare but urgently in demand. Here, we provide evidence that
BRP-7, a recently identified hit from an in silico FLAP inhibi-
tor discovery approach (Banoglu et al., 2012), acts on FLAP
and thereby efficiently suppresses 5-LOX product synthesis in
vitro and in vivo with anti-inflammatory effectiveness. Our
results demonstrate that BRP-7 (i) efficiently inhibits cellular
5-LOX product synthesis and shares typical features of FLAP
inhibitors; (ii) interferes with 5-LOX subcellular localization
and co-localization with FLAP; (iii) does not inhibit other
related or relevant enzymes involved in AA metabolism; (iv)
does not interfere with CYP3A4 or hERG in vitro; and (iv) is
effective in HWB and in animal models of acute inflamma-
Figure 5
Effect of BRP-7 on COX-1, COX-2 and mPGES-1 activity. Effect of BRP-7 (10 μM) on the activity of (A) purified ovine COX-1 or (B) human
recombinant COX-2 as measured by HPLC analysis of COX-derived 12-HHT after incubation with AA (5 and 2 μM, for COX-1 and COX-2
respectively). Effect of BRP-7 (10 μM) on the activity of (C) COX-1 by HPLC analysis of 12-HHT production in freshly isolated human platelets
stimulated with 5 μM AA or of (D) COX-2 by EIA analysis of 6-keto PGF1α in IL-1β-stimulated A549 cells treated with 3 μM AA. (E) Effect of BRP-7
(10 μM) on mPGES-1 activity, measured by HPLC analysis of PGE2 produced in microsomes of IL-1β-stimulated A549 cells treated with 20 μM
PGH2. (A–D) 10 μM indomethacin (indo) and (E) 10 μM MK886 were used as positive controls. The 100% controls correspond to (A) 132.0 ±
13.2 ng·mL−1 12-HHT; (B) 103.8 ± 13.4 ng·mL−1 12-HHT; (C) 138.5 ± 24.1 ng·mL−1 12-HHT; (D) 406.8 ± 145.9 pg·mL−1 6-keto PGF1α; (E) 1.1 ±
0.2 nmol PGE2 in 100 μL reaction buffer. Data are expressed as percentage of stimulated vehicle control (100%) and are means + SEM; n = 3–5;
*P < 0.05; ***P < 0.001 versus 100% control; ANOVA plus Bonferroni.
Table 1
Effect of BRP-7 on carrageenan-induced pleurisy in rats
Treatmenta LTB4 (ng pro rat)b
Exudate volume
(mL)b
Inflammatory
cells (× 106)b
Vehicle 0.573 ± 0.130 0.45 ± 0.13 50.0 ± 7.2
10 mg·kg−1 BRP-7 0.505 ± 0.092 0.14 ± 0.09* 31.0 ± 1.6**
88.2% 31.1% 62.0%
20 mg·kg−1 BRP-7 0. 314 ± 0.078 0.20 ± 0.08* 26.7 ± 3.2***
54.8% 44.4% 53.4%
30 mg·kg−1 BRP-7 0.157 ± 0.028 0.03 ± 0.08** 18.6 ± 3.9**
27.4% 6.6% 37.2%
1 mg·kg−1 MK886 0.113 ± 0.032 0.08 ± 0.08** 36.7 ± 2.7*
19.7% 17.7% 73.4%
Data are means ± SEM, n = 4–7. Values in italics are percentage of vehicle control.
aMale rats (n = 5–7) were treated i.p. with 10, 20 or 30 mg·kg−1 BRP-7, vehicle (4% DMSO) or 1 mg·kg−1 MK886, as indicated, 30 min before
intrapleural injection of carrageenan.
bAnalysis was performed 4 h after carrageenan injection.
*P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle (ANOVA + Bonferroni).
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tion and this is accompanied by reduced LT levels. Therefore,
BRP-7 might represent a novel basic structure for the devel-
opment of alternative FLAP inhibitors suitable for exploita-
tion as tools and/or potential therapeutics.
Pharmacological intervention with the LT pathway
encompasses essentially three different strategies, that is,
inhibition of enzymes involved in LT biosynthesis (e.g.
5-LOX, LTA4 hydrolase or LTC4 synthase), antagonism of LT
Figure 6
BRP-7 suppresses 5-LOX product formation in human whole blood. Effect of BRP-7 on (A) 5-LOX product formation in human whole blood
stimulated with LPS (1 μg·mL−1; 30 min, 37°C) and fMLP (1 μM; 15 min, 37°C). BRP-7 or vehicle (0.1% DMSO) were added 10 min before fMLP.
5-LOX products were assessed by HPLC and are means + SEM of percentage of vehicle control (100%, corresponding to 41.3 ± 6.5 ng·mL−1, n
= 6); (B) LTB4 levels in carrageenan-induced pleurisy in rats; (C) LTC4 levels in zymosan-induced peritonitis in mice. In (B) and (C), male rats or
mice (n = 5–7, each group) were treated i.p. with 10, 20 or 30 mg·kg−1 BRP-7, 1 mg·kg−1 MK886 or vehicle (4 or 2% DMSO, for rat pleurisy and
mouse peritonitis, respectively), 30 min before (B) intrapleural injection of carrageenan or (C) i.p. injection of zymosan. Analysis was performed
(B) 4 h after carrageenan injection or (C) 30 min after zymosan injection. Data are means + SEM % of vehicle control; 100% corresponds to (B)
0.573 ± 0.130 ng·mL−1 LTB4 or (C) 142.3 ± 17.1 ng·mL−1 LTC4. **P < 0.01; ***P < 0.001 versus vehicle control; ANOVA plus Bonferroni.
Table 2
Effect of BRP-7 on zymosan-induced peritonitis in mice
Treatmenta LTC4 (ng·mL−1)b
Vascular permeability
(A650)b
Inflammatory
cells (× 106)c
Vehicle 144.1 ± 20.0 1.35 ± 0.12 24.5 ± 1.9
BRP-7 70.4 ± 16.0* 0.84 ± 0.09* 17.7 ± 1.0**
48.8% 62.2% 69.7%
MK886 7.5 ± 1.6*** 0.32 ± 0.05*** 16.1 ± 0.5**
5.2% 23.7% 63.4%
Data are means ± SEM, n = 6. Values in italics are percentage of vehicle control.
aMale mice (n = 6, each group) were treated i.p. with 20 mg·kg−1 BRP-7, 1 mg·kg−1 MK886 or vehicle (2% DMSO), 30 min before i.p. injection
of zymosan.
bAnalysis was performed 30 min after zymosan injection.
cAnalysis was performed 4 h after zymosan injection.
*P < 0.05; **P < 0.01; ***P < 0.001 versus vehicle (Student’s t-test).
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receptors (e.g. the cysLT1 antagonist montelukast) and inhi-
bition of LT formation by interference with FLAP. As com-
pared to LT receptor antagonism and to inhibition of LTA4
hydrolase or LTC4 synthase, targeting 5-LOX or FLAP appears
advantageous because it leads to suppression of both classes
of LTs (LTB4 and cysLT) and is appealing for its higher efficacy
as an anti-inflammatory therapy. Although the possibility of
direct inhibition of 5-LOX as a medical intervention has been
extensively explored, the successful development of 5-LOX
inhibitors has been strongly hampered due to their toxicity or
lack of in vivo efficacy (Pergola and Werz, 2010), and until
today, only one 5-LOX inhibitor (zileuton) could possibly
enter the market.
In contrast, targeting FLAP has demonstrated promise in
animal studies and in early clinical phases, but no FLAP
inhibitor has yet received marketing authorization (Hofmann
and Steinhilber, 2013). In fact, the discovery and evaluation
of new FLAP-interfering chemotypes has been strongly
limited by the fact that FLAP has no specific enzymatic func-
tionality, which might be utilized as a measure for a simple
and convenient compound screening approach. For this
reason, experimental evidence for direct and functional FLAP
targeting is limited and pharmacological evaluation of FLAP
inhibitors has to rely on comparative analysis with previously
recognized compounds (e.g. in terms of inhibition of 5-LOX
product formation in cellular assays without direct 5-LOX
inhibition), which has hampered the identification of novel
clinically relevant compounds. In fact, research has mainly
focused upon the structural optimization of the only two
known chemotypes for FLAP inhibition, that is, the indole
and quinoline cores (Sampson, 2009). Interestingly, the
crystal structure of FLAP bound to two inhibitors has recently
been elucidated and these studies have also provided func-
tional insights into the role of FLAP in aiding 5-LOX for LTA4
synthesis, by revealing the location of the inhibitor-binding
site (Ferguson et al., 2007; Ferguson, 2012). Although the
resolution of the FLAP structure was too low for reliable
structure-based design, we made use of the structural knowl-
edge and combined it with ligand-based evidence to imple-
ment a rapid virtual screening strategy for the identification
of new chemotypes for FLAP inhibitors (Banoglu et al., 2012).
Screening of a pre-compiled collection of 2.8 mio vendor
compounds (153 mio conformations) using this three-
dimensional pharmacophore query led to 1792 compounds
matching the desired pharmacophoric features, and after
filtering according to forcefield refinement and rescoring
function, 192 virtual hits remained. Then by use of protein–
ligand interaction fingerprint application of MOE, BRP-7 was
revealed as the overall hit, but its pharmacological profile
remained unexplored.
BRP-7, a non-acidic benzimidazole derivative bearing the
isobutylphenylethyl fingerprint of ibuprofen, is a novel struc-
ture that lacks typical pharmacophoric moieties of FLAP
inhibitors, such as indole core, carboxylic acid or a quinoline
residue (Evans et al., 2008; Sampson, 2009). Our present data
show that BRP-7 displays the typical profile of FLAP inhibi-
tors and exhibits pharmacological properties, which support
its further development, that is, in vivo efficacy. Thus, similar
to other FLAP inhibitors that typically fail to inhibit soluble
5-LOX in cell-free assays (Miller et al., 1990; Hatzelmann
et al., 1993), BRP-7 failed to inhibit the activity of 5-LOX in
cell homogenates (neutrophils and monocytes) or to inhibit
isolated human recombinant 5-LOX at concentrations up to
100-fold higher than those needed to block cellular 5-LOX
product synthesis by 50%. Similar features were observed for
the FLAP inhibitor MK-866, whereas the direct 5-LOX inhibi-
tor zileuton (Carter et al., 1991) blocked 5-LOX activity in
the cell-free assay equally well as in intact neutrophils, as
expected.
A strong loss of potency in cell-free assays also holds true
for direct 5-LOX inhibitors of the non-redox type, because of
the lack of a reducing environment (Werz et al., 1998; Fischer
et al., 2004), and this may also apply to BRP-7. However, unlike
the non-redox-type 5-LOX inhibitors (Werz et al., 1998;
Fischer et al., 2004), supplementation of neutrophil homoge-
nates with GSH did not confer 5-LOX inhibitory properties to
BRP-7, implying that the failure of BRP-7 to inhibit 5-LOX in
cell-free assays is not due to a lack of reducing environment,
but rather suggesting that BRP-7 acts on FLAP.
As FLAP may confer high 5-LOX-mediated product syn-
thesis by increasing the utilization of endogenously released
AA by 5-LOX (Abramovitz et al., 1993; Ferguson, 2012), exog-
enous addition of AA as a substrate to some extent circum-
vents the requirement of FLAP. Accordingly, the potency of
BRP-7 in the presence of exogenously added AA was reduced
and no reduction of AA release was observed, again suggest-
ing that BRP-7 interfers with FLAP. Finally, FLAP bound to the
BRP-7-affinity matrix 1b more than the control matrix 2b
carrying an inactive analogue, and this was reduced after
competition with free BRP-7. Note that as compared to other
FLAP inhibitors such as MK-866, BRP-7 showed a certain
degree of selectivity with respect to other AA metabolizing
enzymes (e.g. COX, 12/15-LOX) and MAPEG (e.g. mPGES-1).
These data confirm the inhibition of AA transfer to 5-LOX as
a primary effect of FLAP-interference, as suggested by previ-
ous studies (Ferguson et al., 2007). Interestingly, these effects
on 5-LOX translocation and 5-LOX/FLAP localization were
only observed at higher concentrations than those required
for inhibition of LTs, suggesting that BRP-7’s direct effects on
the interaction between 5-LOX and FLAP may be a secondary
effect. It is notable that BRP-7 showed a higher potency in
monocytes than in neutrophils, which may relate to differ-
ences in the role of FLAP or variations in the accessibility of
the compound to the nuclear membrane between the differ-
ent cell types.
BRP-7 suppressed 5-LOX product formation in HWB and
was effective in vivo in reducing LT levels and the inflamma-
tory reaction, as observed in two well-recognized models of
acute inflammation (i.e. carrageenan-induced pleurisy in rats
and zymosan-induced peritonitis in mice). This is in contrast
to several 5-LOX inhibitors, which are often found to be
inactive under these conditions (Pergola and Werz, 2010).
Although the actual potency of BRP-7 appears slightly lower
as compared to optimized indole- or quinoline-containing
derivatives, the chemical nature of BRP-7 and its synthetic
accessibility offer several possibilities for lead optimization.
Importantly, we did not observe significant inhibition of
CYP3A4 by BRP-7, whereas CYP inhibition has been a critical
issue for certain FLAP inhibitors (Hutchinson et al., 2009).
Indeed, BRP-7 was also inactive on hERG and did not show
significant cellular toxicity or obvious toxic effects in mice
and rats. Together, we propose BRP-7 as novel chemotype that
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inhibits LT biosynthesis by targeting FLAP, without affecting
related enzymes, such as 5-LOX, 12/15-LOX, COX-1, COX-2
and mPGES-1, but with pharmacological relevance in vivo and
potential for further development as a lead compound.
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